MedTech Business - December 3, 2025
Photocure wins the Norwegian Cancer Society Innovation Prize
Ingrid Stenstadvold Ross, Secretary-General of the Norwegian Cancer Society, presented the innovation award, accompanied by a prize of NOK 300,000, to the bladder cancer company Photocure. “Building on our success and expertise, we aim to create a suite of complementary precision diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare […]
Biotech Business - August 27, 2025
Nykode Therapeutics announces updated strategy
The updated strategy includes prioritization of VB10.16 as the lead clinical asset and value driver, given the company’s increasing conviction in its potential to treat HPV16 positive cancers.
Acquisition - August 5, 2025
BerGenBio and Oncoinvent to merge
On June 30 2025, BerGenBio and Oncoinvent announced that they have entered into a merger agreement to combine the two companies through a statutory merger, where BerGenBio will be the acquiring entity.
Agreement - March 28, 2025
OncoZenge in agreement for the commercialization of BupiZenge in Europe
The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.
Business article - March 5, 2025
Zelluna announces the successful completion of a business combination
All conditions for completion of the business combination have been met, including, confirmation by Euronext Oslo Børs of the continued listing, approval of the prospectus and regulatory clearances, the new company states.
Norway - February 18, 2025
Norway: New national cancer strategy presented
With the new national cancer strategy, Minister Vestre vows to make Norway world-leading in cancer. Here are Oslo Cancer Cluster's reactions.
